Vland Biotech(SH:603739)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥232,557,094.68, representing a decrease of 9.14% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥10,562,755.37, down 41.59% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,780,045.44, a decline of 60.66% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.04, reflecting a decrease of 42.86% year-on-year[5] - Total operating revenue for Q1 2023 was ¥232,557,094.68, a decrease of 9.1% compared to ¥255,961,097.43 in Q1 2022[15] - Net profit for Q1 2023 was ¥12,552,054.99, a decline of 36.8% from ¥19,848,538.25 in Q1 2022[16] - Total comprehensive income for Q1 2023 was CNY 12,479,517.70, a decrease of 36.9% from CNY 19,790,305.06 in Q1 2022[17] - Basic and diluted earnings per share for Q1 2023 were CNY 0.04, down from CNY 0.07 in Q1 2022[17] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥2,629,967,029.91, an increase of 1.98% from the end of the previous year[6] - The company's total assets increased to ¥2,629,967,029.91 in Q1 2023, up from ¥2,578,847,636.98 in Q1 2022, reflecting a growth of 2.0%[13] - Total liabilities rose to ¥884,744,898.05 in Q1 2023, compared to ¥844,934,231.18 in Q1 2022, marking an increase of 4.7%[12] - The equity attributable to shareholders at the end of Q1 2023 was ¥1,660,757,522.07, up 0.98% from the end of the previous year[6] - The total equity attributable to shareholders increased to ¥1,660,757,522.07 in Q1 2023, compared to ¥1,644,694,382.39 in Q1 2022[13] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥13,421,624.00, not applicable for year-on-year comparison[5] - Net cash flow from operating activities was CNY 13,421,624.00, compared to a negative cash flow of CNY -11,679,628.80 in the same period last year[18] - Net cash flow from investing activities was CNY -107,823,654.78, an improvement from CNY -194,348,403.12 in Q1 2022[19] - Cash inflow from financing activities was CNY 98,389,603.20, an increase from CNY 90,000,000.00 in Q1 2022[19] - Cash outflow for repayment of debts was CNY 20,200,000.00, compared to CNY 5,000,000.00 in Q1 2022[19] - The company reported a decrease in cash flow from operating activities related to other business activities, totaling CNY 9,119,903.24, down from CNY 19,805,193.77 in Q1 2022[18] Expenses - Total operating costs for Q1 2023 were ¥228,356,493.21, down 6.0% from ¥242,656,388.86 in Q1 2022[15] - Research and development expenses for Q1 2023 were ¥22,660,128.74, a decrease of 4.6% from ¥23,745,421.82 in Q1 2022[15] - The company’s financial expenses rose to ¥2,799,419.24 in Q1 2023, up from ¥716,697.27 in Q1 2022, indicating a significant increase in interest expenses[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,314[8] - The company reported non-recurring gains of ¥6,782,709.93 for the period, after accounting for tax effects and minority interests[7] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with Q1 2022[17] Cash and Cash Equivalents - The company's cash and cash equivalents increased to ¥975,341,333.35 in Q1 2023, slightly up from ¥969,399,325.09 in Q1 2022[12] - Cash and cash equivalents at the end of the period were CNY 181,670,560.69, slightly down from CNY 184,046,470.97 at the end of Q1 2022[19] - Revenue from sales of goods and services received cash of CNY 293,060,884.07, an increase of 9.9% from CNY 266,566,667.91 in Q1 2022[18] - The company reported an investment income of ¥4,739,753.75 in Q1 2023, significantly higher than ¥555,766.54 in Q1 2022[16]